Researcher
Max Mazzone
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Mazzone Max (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Mazzone Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → 30 Sep 2022
Projects
1 - 10 of 63
- Targeting the DNA methylation profile of cytotoxic T cells to overcome immunotherapy resistance of pancreatic cancerFrom5 Mar 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding glutamate metabolism in the tumor microenvironment to tackle Immune Checkpoint Blockade (ICB) resistanceFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Role of SLC1A3 in tumor-associated macrophages during immunotherapy resistance onset in breast cancerFrom1 Oct 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Targeting the CDA/P2Y6 axis to overcome immunosuppression and favor response to immune checkpoint inhibitors in pancreatic cancerFrom1 Jul 2023 → TodayFunding: Other federal public and semi-governmental institutions
- Tackling tumor immunosuppression by reprograming eicosanoid metabolism and signaling in the tumor microenvironmentFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Understanding the roles of the epigenetic machinery in shaping distinct tumor-associated macrophage phenotypes.From10 Nov 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Tackling SLC1A3 in tumor-associated macrophages to overcome anti-PD1 immunotherapy resistance in breast cancerFrom31 Oct 2022 → TodayFunding: FWO Strategic Basic Research Grant
- LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- BD Imaging Cell Sorter – BD Cell View TechnologyTMFrom24 Jun 2022 → TodayFunding: Other federal scientific institutions
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
Publications
31 - 40 of 182
- Tumor vessel co-option probed by single-cell analysis(2021)
Authors: Laure-Anne Teuwen, Laura De Rooij, Sébastien Dumas, Stefaan Soenen, Guy Eelen, Mieke Dewerchin, Max Mazzone, Peter Carmeliet
- Hypoxia-induced miR-210 modulates the inflammatory response and fibrosis upon acute ischemia (vol 12, 435, 2021)(2021)
Authors: Germana Zaccagnini, Simona Greco, Marialucia Longo, Biagina Maimone, Christine Voellenkle, Paola Fuschi, Matteo Carrara, Pasquale Creo, Davide Maselli, Mario Tirone, et al.
- BNIP3 promotes HIF-1α-driven melanoma growth by curbing intracellular iron homeostasis(2021)
Authors: Matteo Rossi, Chris Van den Haute, Maria Livia Sassano, Abhishek Garg, Francesca Bosisio, Jasper Wouters, Peter Vangheluwe, Wim Annaert, Johan Swinnen, Joost van den Oord, et al.
- Protein Phosphatase 2A Mediates YAP Activation in Endothelial Cells Upon VEGF Stimulation and Matrix Stiffness(2021)
Authors: Mario di Matteo, Max Mazzone
- Neutrophils fuel effective immune responses through gluconeogenesis and glycogenesis (vol 33, 411.e1, 2021)(2021)
Authors: Pranvera Sadiku, Joseph A Willson, Eilise M Ryan, David Sammut, Patricia Coelho, Emily R Watts, Robert Grecian, Jason M Young, Martin Bewley, Simone Arienti, et al.
Pages: 1062 - 1064 - How metabolism bridles cytotoxic CD8+T cells through epigenetic modifications(2021)
Authors: Tommaso Scolaro, Max Mazzone
Pages: 401 - 417 - Hypoxia-induced miR-210 modulates the inflammatory response and fibrosis upon acute ischemia.(2021)
Authors: Zaccagnini Germana, Greco Simona, Longo Marialucia, Maimone Biagina, Voellenkle Christine, Fuschi Paola, Carrara Matteo, Creo Pasquale, Maselli Davide, Tirone Mario, et al.
Pages: 435 - Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation(2021)
Authors: Federico Virga, Federica Cappellesso, Rosa Trotta, Lies Langouche, Greet Van den Berghe, Max Mazzone
- Metabolic traits ruling the specificity of the immune response in different cancer types(2021)
Authors: Federica Cappellesso, Samantha Pretto, Max Mazzone
Pages: 124 - 143 - IL1β Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D(2021)
Authors: Jun Qian, Samantha Pretto, Diether Lambrechts, Max Mazzone
Pages: 309 - 323
Patents
1 - 10 of 10
- Cd8+ t-cells lacking plexins and their application in cancer treatment (Inventor)
- Cancer treatment by targeting plexins in the immune compartment (Inventor)
- Biomarker for anti-tumor therapy (Inventor)
- Inhibition of slc4a4 in the treatment of cancer (Inventor)
- Combination of p2y6 inhibitors and immune checkpoint inhibitors (Inventor)
- Means and methods to treat inflammatory diseases (Inventor)
- Glutamine dehydrogenase inhibitors for use in muscle regeneration (Inventor)
- Cd8+ t-cells lacking plexins and their application in cancer treatment (Inventor)
- Podoplanin positive macrophages (Inventor)
- Cancer treatment by targeting plexins in the immune compartment (Inventor)